abstract |
Disclosed are adamantylaminocarbonyl compounds of formula (I), wherein the substituents are as defined in the specification, that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Also disclosed is the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action. |